Amoeba SA (ALMIB) - Total Liabilities

Latest as of December 2025: €15.49 Million EUR ≈ $18.11 Million USD

Based on the latest financial reports, Amoeba SA (ALMIB) has total liabilities worth €15.49 Million EUR (≈ $18.11 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Amoeba SA - Total Liabilities Trend (2011–2025)

This chart illustrates how Amoeba SA's total liabilities have evolved over time, based on quarterly financial data. See ALMIB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Amoeba SA Competitors by Total Liabilities

The table below lists competitors of Amoeba SA ranked by their total liabilities.

Company Country Total Liabilities
Ramssol Group Bhd
KLSE:0236
Malaysia RM52.71 Million
Akme Fintrade India Ltd
NSE:AFIL
India Rs5.10 Billion
TETHYS PETROLEUM LTD
F:TP21
Germany €33.97 Million
Hindustan Media Ventures Limited
NSE:HMVL
India Rs8.78 Billion
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
USA $49.69 Million
Vow ASA
OL:VOW
Norway Nkr849.80 Million
Clime Capital Ltd
AU:CAM
Australia AU$43.06 Million
International Media Acquisition Corp
NASDAQ:IMAQ
USA $15.25 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Amoeba SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Amoeba SA (ALMIB) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.98 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.89 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.53 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Amoeba SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Amoeba SA (2011–2025)

The table below shows the annual total liabilities of Amoeba SA from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 €15.49 Million
≈ $18.11 Million
-3.54%
2024-12-31 €16.06 Million
≈ $18.78 Million
+56.99%
2023-12-31 €10.23 Million
≈ $11.96 Million
+141.99%
2022-12-31 €4.23 Million
≈ $4.94 Million
-70.44%
2021-12-31 €14.30 Million
≈ $16.72 Million
+29.28%
2020-12-31 €11.06 Million
≈ $12.93 Million
+15.09%
2019-12-31 €9.61 Million
≈ $11.24 Million
+112841.62%
2018-12-31 €8.51K
≈ $9.95K
-6.05%
2017-12-31 €9.06K
≈ $10.59K
+93.31%
2016-12-31 €4.69K
≈ $5.48K
+32.52%
2015-12-31 €3.54K
≈ $4.13K
-99.87%
2014-12-31 €2.75 Million
≈ $3.22 Million
+52.76%
2013-12-31 €1.80 Million
≈ $2.11 Million
+133.74%
2012-12-31 €770.75K
≈ $901.09K
+16.57%
2011-12-31 €661.17K
≈ $772.98K
--

About Amoeba SA

PA:ALMIB France Agricultural Inputs
Market Cap
$68.48 Million
€58.57 Million EUR
Market Cap Rank
#20754 Global
#325 in France
Share Price
€0.75
Change (1 day)
-1.05%
52-Week Range
€0.75 - €1.16
All Time High
€38.22
About

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more